Mesa Laboratories, Inc.·Technology

LAKEWOOD, Colo. , April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0. 16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.

Mesa Laboratories, Inc. (NASDAQ: MLAB - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $79.16 and traded as high as $82.50. Mesa Laboratories shares last traded at $81.13, with a volume of 99,075 shares traded. Analyst

Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.

Principal Financial Group Inc. lessened its stake in Mesa Laboratories, Inc. (NASDAQ: MLAB) by 66.2% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,065 shares of the medical instruments supplier's stock after selling 19,713 shares during the quarter. Principal Financial Group

Diamond Hill Capital Management Inc. grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ: MLAB) by 218.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,381 shares of the medical instruments supplier's stock after purchasing an additional 84,582

Mesa Laboratories (NASDAQ: MLAB - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of $2.41 per share and revenue of $63.2330 million for the quarter. Individuals may visit the the company's upcoming Q3 2026 earning results page for
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Technology
Hardware, Equipment & Parts
736
1984-02-29
0.89